HIV seroconversion in intravenous drug users in San Francisco, 1985-1990.
about
Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysisHIV prevalence, risk behaviors, health care use, and mental health status of transgender persons: implications for public health interventionSex-specific determinants of HIV infection among injection drug users in MontrealChanges in HIV incidence among people who inject drugs in Taiwan following introduction of a harm reduction program: a study of two cohortsHIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco.Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City.HIV and hepatitis B and C incidence rates in US correctional populations and high risk groups: a systematic review and meta-analysis.HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial.Syringe exchange programs: lowering the transmission of syringe-borne diseases and beyondDrug abuse treatment as AIDS prevention.Facilitating treatment entry among out-of-treatment injection drug users.Reducing HIV-related risk behaviors among injection drug users in residential detoxificationAssessing the effects of human mixing patterns on human immunodeficiency virus-1 interhost phylogenetics through social network simulation.Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection.Changes in blood-borne infection risk among injection drug users.Correlates of risky injection practices among past-year injection drug users among the US general populationDrug treatment as HIV prevention: a research updateHIV prevention among injection drug users: the need for integrated models.Progress in HIV reduction and prevention among injection and noninjection drug users.Preventing HIV in injection drug users: choosing the best mix of interventions for the population.Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle areaRecruiting drug-using men who have sex with men into behavioral interventions: a two-stage approachIncidence of HIV among injection drug users entering drug treatment programs in four US cities.Risk-taking behaviors among injecting drug users who obtain syringes from pharmacies, fixed sites, and mobile van needle exchanges.HIV among people who inject drugs in Central and Eastern Europe and Central Asia: a systematic review with implications for policy.Social contextual factors associated with entry into opiate agonist treatment among injection drug usersHigh-risk sexual and drug using behaviors among male injection drug users who have sex with men in 2 Mexico-US border citiesThe urgent need for HIV and hepatitis prevention in drug treatment programs in HungaryHepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenanceOptimal investment in HIV prevention programs: more is not always betterWhy don't out-of-treatment individuals enter methadone treatment programmes?Effect of low-threshold methadone maintenance therapy for people who inject drugs on HIV incidence in Vancouver, BC, Canada: an observational cohort study.Measures of human immunodeficiency virus (HIV) community viral load and HIV incidence among people who inject drugs.HIV transmission and the cost-effectiveness of methadone maintenance.
P2860
Q22242071-AB6D510A-EAAB-422D-9F99-66F2BB551490Q24544067-8F63C7EC-5F3F-49B0-9D6E-C6B1EB4D22BFQ28361596-8949164F-4B72-41FB-8B0D-EDBAD22D69D3Q28542085-AEEC206F-15A6-4C8E-8B0B-3C63D2879382Q30226766-36C78582-3157-4568-943F-C3AF29A9C515Q32030710-6B3727BF-AFD3-4393-BAD1-40718231D4D1Q33777428-D47FC0A7-7595-4868-8C1E-EF504449753DQ34098066-3C8DE6F5-B35A-484B-83FF-FB60492EF018Q34196397-982A7E0F-767D-4D45-95B6-5BE3F77189DDQ34196421-5585B230-9797-48F1-B6F4-A8778EC63F02Q34196435-2DF725A6-8BD0-4156-81AD-4A550795BC8FQ34504608-B7BCCE57-44F8-4829-AF40-3F1EA33C650FQ34588670-3A7E4DCE-3C58-4A5D-84DC-D72B76A98FEFQ34704122-F9EA1528-C0A1-475E-8E01-3C6EA5D05A24Q34772870-6D57CB57-D653-4902-BDB8-3EE7AD4171F0Q34959214-130DA185-7750-4B84-9646-D26100162287Q35163392-A5D183CA-98D4-4970-B3CE-4266964FD529Q35624688-C07723B0-B185-451E-BB42-6796D16064F6Q35816921-9BDFE414-006C-471F-B989-E98BC9A61CCDQ36272465-7ACE02A4-8C0C-4F41-8F79-D0F6AA03814BQ36272739-AAE46802-5230-4CBD-81D1-24019E54A88BQ36273173-BAFAA093-2023-4640-883F-59E6235C73B4Q36273258-5244A745-2E84-4433-A06A-7942BDC67367Q36275042-46F359A3-59B0-4340-8E17-1AFBF7FF1FC2Q36370253-5ADA5F3B-A4D3-4F97-BAC4-CB2DD661BAEDQ36376978-41A925FE-A5FB-4D92-B3E7-92717BD925A1Q36667966-746DB481-387E-476F-97EF-D53647448D63Q36925071-63D498D6-13E5-4D3F-8F91-816D889455C8Q37011167-571AD937-0DDC-4D00-92DE-111EBDD0F1EAQ37449817-FA9F92E9-7008-4E82-85B3-8C37A6493591Q37466048-22394545-8E90-411F-9E58-F26C617371CBQ40481128-61EE0EB6-FC68-4435-9E2F-7F2DC7672E11Q45324639-C6FB839E-0E78-47AA-8B98-FE5B4C2DB7B5Q52278638-7FB9853F-A91D-4816-AC2C-EC5775CF27D8
P2860
HIV seroconversion in intravenous drug users in San Francisco, 1985-1990.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
HIV seroconversion in intravenous drug users in San Francisco, 1985-1990.
@ast
HIV seroconversion in intravenous drug users in San Francisco, 1985-1990.
@en
type
label
HIV seroconversion in intravenous drug users in San Francisco, 1985-1990.
@ast
HIV seroconversion in intravenous drug users in San Francisco, 1985-1990.
@en
prefLabel
HIV seroconversion in intravenous drug users in San Francisco, 1985-1990.
@ast
HIV seroconversion in intravenous drug users in San Francisco, 1985-1990.
@en
P2093
P1433
P1476
HIV seroconversion in intravenous drug users in San Francisco, 1985-1990.
@en
P2093
P304
P407
P577
1994-02-01T00:00:00Z